Benzinga

Benzinga

Benzinga

sábado, agosto 22

Neuphoria Therapeutics Inc

NEUPNASDAQ
Trade with Public
Trade with Public
$3.91
-0.04-1.01%
al cierre: Aug 21, 5:00 PM EST
$3.92
0.0110.28%
After hour: 9:18 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Neuphoria Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Neuphoria Therapeutics (NEUP).

Price Target Range — 3 Quarters

Analyst Consensus — 2 Analysts

1Buy
1Hold
Consensus RatingBuy# Analysts2Avg. Consensus PT$35Upside to Avg. PT+792.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
May 15, 2026HC Wainwright & Co.Joseph PantginisDowngradeBuy→Neutral—
Dec 5, 2025HC Wainwright & Co.Joseph PantginisPT CutBuy$21→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Neuphoria Therapeutics (NASDAQ:NEUP) from Buy to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Lowers Price Target to $7

HC Wainwright & Co. analyst Joseph Pantginis maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and lowers the price target from $21 to $7.
Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $35

Maxim Group analyst Jason McCarthy maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $18 to $35.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Neuphoria Therapeutics, Maintains $21 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and maintains $21 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Raises Price Target to $21

HC Wainwright & Co. analyst Joseph Pantginis maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and raises the price target from $8 to $21.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved